BOTHELL, Wash.--(BUSINESS WIRE)--Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today highlighted corporate progress and reported financial results for the second quarter of 2007. At 8:30 A.M. PT/11:30 A.M. ET today, Sonus will host its quarterly conference call.
“As we move into the second half of 2007, we remain focused on two key strategic objectives, the most important of which is to secure independently-reviewed data from the pivotal Phase 3 trial of TOCOSOL Paclitaxel,” said Michael A. Martino, President and Chief Executive Officer of Sonus Pharmaceuticals. “The results from the Phase 3 trial are still expected to be available by the end of the third quarter. We continue to believe in the opportunity for TOCOSOL Paclitaxel, and our ultimate goal is to bring the potential benefits of this drug to patients and health care providers. We also remain focused on the implementation of the Phase 1 study for TOCOSOL Camptothecin, our second product candidate, with an objective of obtaining preliminary safety and efficacy data by year-end.”